AstraZeneca's New Injectable C5 Drug for gMG Shows Promising Results
AstraZeneca has announced positive results for its new injectable C5 drug, gefurulimab, which could provide patients with generalized myasthenia gravis (gMG) with a self-administered treatment option at home.
The PREVAIL study demonstrated that gefurulimab achieved a statistically significant improvement in gMG symptoms, with a 1.6-point improvement in MG-ADL scores compared to placebo, considered "clinically meaningful" by AstraZeneca.
- 1.8-point improvement in the QMG scale total score at week four
- 2.1-point improvement at week 26
AstraZeneca's gefurulimab could give gMG patients the first treatment option that they can self-administer at home once a week
AstraZeneca's Alexion unit developed gefurulimab, a nanobody that shows promise in treating gMG.
Author's summary: AstraZeneca's gefurulimab shows promising results for gMG treatment.